IFN-α based immunotherapies were used for the treatment of lymphomas both of B- and T-cell origin [244,245], possibly exerting a part of their therapeutic effect via mitigating the degree NLRP3 inflammasome activation. Here, NLRP3 is linked to lymphoma.